SANTA CLARA, CA, June 15 /PRNewswire/ -- Applied Imaging Corp.
(Nasdaq: AICX) ( http://www.aicorp.com ) announced that it has signed a multiple-year
distribution and product development agreement with Digital Scientific, Ltd, a
UK-based designer of novel imaging tools for advanced fluorescence microscopy.
Under the terms of this agreement, Applied Imaging will be the exclusive
worldwide distributor of Digital Scientific's SmartCapture family of products.
These innovative fluorescence imaging applications will be incorporated into
the Quips(R) PathVysion(TM) system, designed to assist pathology labs with the
more accurate documentation of three-dimensional, multi-color images of tissue
and biopsy specimens.
"We are pleased to have formalized this relationship with Digital
Scientific, a long-term partner in the development of Quips imaging systems,"
stated Carl Hull, President and Chief Operating Officer of Applied Imaging.
"Working together, we plan to add new capabilities, such as automated
microscope control and integrated results reporting, to our Apple(R)
Macintosh(R)-based systems. These new systems will further extend Applied
Imaging's lead in providing fluorescent image analysis capabilities to
laboratories studying genetic abnormalities in cancer and prenatal disorders
utilizing DNA probes. We expect to introduce these systems later this
summer," added Hull.
Applied Imaging Corp., based in Santa Clara, California, is the leading
supplier of automated imaging systems utilized in genetics and pathology
laboratories for the analysis of chromosomes in cancer and prenatal disorders.
The Company is expanding its product line for scanning and imaging
applications in the cancer pathology field. Applied Imaging has installed
over 1800 systems in 800 laboratories in more than 35 countries. Applied
Imaging is a publicly traded company listed on the Nasdaq Stock Market under
the symbol AICX.
Digital Scientific Limited, Cambridge, UK, is a privately owned company
established in 1991 to develop software for the control and management of high
performance cooled cameras and automated microscope systems primarily used for
fluorescence imaging. SmartCapture software is used in over 700 research
laboratories worldwide engaged in molecular cytogenetics and fluorescence
cytology. SmartCapture 2 -- the latest version -- is exclusively distributed
by Applied Imaging. Further information on Digital Scientific is available on
the web at http://www.digitalscientific.co.uk .
This press release contains forward looking statements as defined in the
Private Securities Litigation Reform Act of 1995, regarding, among other
matters, the Company's research and development and product development
efforts. Forward looking statements address matters that are subject to a
number of risks and uncertainties, including the uncertainty of clinical
studies and regulatory approvals. Actual results could differ materially from
those projected in the forward-looking statement as a result of a number of
factors including the failure of the Company to successfully develop and
commercialize its cytogenetic instrument businesses, and other such factors as
set forth in the Company's form 10-K for the year ended December 31, 1999 as
filed with the Securities and Exchange Commission.
For additional information on Applied Imaging via fax, please dial
1-800-PRO-INFO, (732-544-2850 outside of the U.S.), code AICX.
SOURCE Applied Imaging Corp.
 back to top
Related links:
http://www.aicorp.com
CONTACT:
Carl Hull, President of Applied Imaging,
408-562-0250; Colin Grace, Director, of Digital Scientific,
44-0-1223-329-993; or General Info, Joann Mahaffey, Investor,
James Hoyne, Media, Chris Cook, 415-986-1591, all of The
Financial Relations Board for Applied Imaging Corp.
|
